| Molecular Medicine SpA is a medical biotechnology company which focuses on the research, development and clinical validation of therapies to treat cancer. The company's approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. Its pipeline includes antitumor therapeutics in clinical and preclinical development: Zalmoxis (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression. |
|
